Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't bother with him too much ..... he's here too, among us - let him do his number.
The market still does not seem to appreciate this event too much - eventually it will react positively, just need patience.
I'm not referring to the MCOA but to the whole sector - going back to the MCOA I wrote some time ago that it is worth risking some money at a price of 0.0010.I repeat, risky, to be very well understood - I personally at the price of 0.0010 or maybe below I will buy for $ 10,000.
Not very soon but I don't think it will be more than 6 months, maybe a year.Until then, build a portfolio and get acquainted with the sector.
I'm waiting for $ 165
Buy before it's too late - this stock will soon hit $ 26 - $ 27 and after September 2 we will probably see it around $ 30.
That's right - but until a possible FDA approval, this kind of news will appear - keep the stock "warm"
FROM INVESTORPLACE
Sorrento’s Test Is Much More Useful
The test could also be used to screen individuals for the virus before they enter hospitals, office buildings, and trains. People entering those facilities would just have to arrive at their destinations 30 minutes to an hour early, take the test, (which would be administered by someone with personal protective equipment) and then come back. At that point, it will have been determined whether they have the virus, and the organizations could act accordingly.
Obviously, arriving just a half hour to an hour early is much more practical in many cases than having to arrive a few hours early. Getting to a restaurant, sporting event, train station, hospital or an office an hour early and then needing to wait for an hour is (in most cases) not that much of an inconvenience. Conversely, having to arrive at those places even a few hours early is terribly inconvenient and sometimes not at all practical.
The Bottom Line on SRNE Stock
Given its superior convenience and the advantages it gives to many enterprises, Sorrento’s test could very easily proliferate around the world over the next six to eight months. Further, I still believe that the company’s therapies for the coronavirus could be used to treat patients by the end of this year. As a result, I like the shares at this point.
Larry Ramer has conducted research and written articles on U.S. stocks for 13 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been Roku, oil stocks and Snap. You can reach him on StockTwits at @larryramer. As of this writing, he owned shares of Sorrento.
I didn't think about this option but espionage can be a good reason.
Still under the influence of last night's news and I don't think investors have any reason to fear - situations in which companies fire their CEO or CFO we have almost monthly - the last was CEO of Wells Fargo
It will stay at this price for a while - until we have a catalyst-keep an eye on the news
NIO down - any idea why ?
Perfect - I hope he gets approval.
I would not liquidate everything - not before the FDA release - situations in which companies fire their CEO or CFO we have almost monthly - the last was CEO of Wells Fargo
Several hedge funds and other institutional investors have recently added to or reduced their stakes in SRNE. Cormorant Asset Management LP grew its holdings in shares of Sorrento Therapeutics by 25.0% during the 1st quarter. Cormorant Asset Management LP now owns 5,000,000 shares of the biopharmaceutical company’s stock worth $9,200,000 after purchasing an additional 1,000,000 shares during the period. Alliancebernstein L.P. lifted its stake in Sorrento Therapeutics by 146.3% during the 1st quarter. Alliancebernstein L.P. now owns 673,400 shares of the biopharmaceutical company’s stock worth $1,239,000 after acquiring an additional 400,000 shares in the last quarter. Swiss National Bank acquired a new position in Sorrento Therapeutics during the 2nd quarter worth about $1,653,000. JPMorgan Chase & Co. lifted its stake in Sorrento Therapeutics by 584.4% during the 1st quarter. JPMorgan Chase & Co. now owns 280,747 shares of the biopharmaceutical company’s stock worth $517,000 after acquiring an additional 239,729 shares in the last quarter. Finally, Raymond James & Associates lifted its stake in Sorrento Therapeutics by 1,960.7% during the 2nd quarter. Raymond James & Associates now owns 231,829 shares of the biopharmaceutical company’s stock worth $1,456,000 after acquiring an additional 220,579 shares in the last quarter. Institutional investors and hedge funds own 16.14% of the company’s stock.
The Olympia Report
For those who have investments in the cannabis sector-
https://www.marijuanamoment.net/the-fda-is-hiring-a-contractor-to-study-thousands-of-cbd-products/?mc_cid=13795b905e&mc_eid=3cd808b822
Useful information.
I wouldn't rely too much on investorplace analysis - they were often far from reality.
Nice numbers !!!!!
Good news today for the mortgage industry - which gives us hope to see RKT on its way to $ 20 or maybe even $ 21
19,44 $ after hours - nice!!!!!
The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:
The FDA issued Yale School of Public Health an emergency use authorization (EUA) for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples when testing for COVID-19. This molecular test is for the qualitative detection of nucleic acid from SARS-CoV-2 in saliva collected without preservatives in a sterile container from individuals suspected of COVID-19 by their healthcare provider. SalivaDirect does not require any special type of swab or collection device – a saliva sample can be collected in any sterile container. It is also unique because it does not require a separate nucleic acid extraction step. This is significant because the extraction kits used for this step in other tests have been prone to shortages in the past.
As part of the FDA’s effort to protect consumers, the agency issued a joint warning letter with the Federal Trade Commission to SilveryGuy, a company that participates in the Amazon Associates program, for selling fraudulent COVID-19 related products. As an Amazon associate, the company earns commissions by promoting the sale of Colloidal Silver products on the company’s website, with misleading claims that the product can mitigate, prevent, treat, diagnose, or cure COVID-19 in people. Currently, there are no FDA-approved products to prevent or treat COVID-19. Consumers concerned about COVID-19 should consult with their health care provider.
Testing updates:
To date, the FDA has currently authorized 214 tests under EUAs; these include 175 molecular tests, 37 antibody tests, and 2 antigen tests.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
###
Very well summarized - SRNE is an excellent investment opportunity at this time.
November 9
Nice day - on way to 14 $
*NIO shares are trading higher after China's central bank implemented new stimulus measures for the economy. Tesla reported China car registrations hit 11,623 units in July.
Benzinga
Sorrento Therapeutics Fans
@FansSorrento
$srne I think I understand Covi-mobile:
FDA said great test but we want lab so they can keep track of testing results.
So we said what if we created a way, like an app that would be connected to the tests, so results can be catalogued - and each person gets a QR number...
11:26 AM · Aug 17, 2020·Twitter for Android
Hopefully, but it still seems a bit much to me - but I'm here and I'm not short on this stock.
Neither do I - someone from TD is probably working now.
True - only that unfortunately many of the "investors" in this stock do not understand much of what Sorrento is doing - the fact that the FDA has turned its attention to saliva testing is great news for SRNE.Many of these "investors" think the YALE test is bad news for the stock and they are doing it wrong.
Bull & Bear Trading
1) The Yale test is by no means "Free." The lab costs associated with the Yale test will NOT be only $10. Overnight shipping costs to the lab will alone cost $25, maybe $40. Those who know the diagnostics industry understand that you can't get in the door for less than $80, and probably more for Covid testing. So let's dismiss the notion that anything will be free, we should all know better than this.
2) Sorrento CEO Henry Ji has stated that the SRNE-Columbia test might cost only $10. The SRNE test is an on site test that does not require a lab. The SRNE test is much cheaper than the Yale test because there are no shipping and/or lab costs for the SRNE test, but these costs are required for Yale test. ADVANTAGE ON COST GOES TO SORRENTO.
3) The testing space is evolving rapidly. Saliva is the new medium for testing. However, sending anything off to a lab is becoming a deal-breaker because the time delay makes the test almost useless. Labs are going to be removed from the equation. On-site initial testing and confirmation is the new gold standard. SRNE meets this qualification. Yale does not. ADVANTAGE OF NO LAB TESTING REQUIRED GOES TO SORRENTO.
4) The term "rapid testing" is now also evolving. Rapid testing will very soon refer to receiving test results within minutes. Rapid testing will not mean hours, and certainly not days. SRNE's test is only 30-minutes. The Yale test has to be sent off to a lab. Even if the Yale test can be completed in hours, unless somebody has access to a lab, then they must deliver the test to a lab. This time delay is unacceptable. Even if somebody has access to a testing lab, the Yale test will take hours vs SRNE's 30-minute test. Columbia has indicated that the testing time could be as little as 15-minutes if very simple items like pre-heating the bath solution is completed ahead of time. ADVANTAGE OF RAPID TESTING SPEED GOES TO SORRENTO.
5) Sorrento's test is the highest level of both sensitivity and specificity measuring 97% and 100% respectively. Yale's testing capabilities may be much lower. It should be a concern that the Yale researchers have not been forthcoming with their numbers on specificity and sensitivity. Yale has been marketing their test as cheap. Americans want affordable, but highly accurate. The entire world demands that an important Covid test be affordable and highly accurate, not just cheap. In stark contrast, the SRNE-Columbia researchers have clearly stated that 97% sensitivity and 100% specificity are the capabilities of their rapid, saliva-based test. ADVANTAGE OF TESTING ACCURACY GOES TO SORRENTO.
Clearly, Sorrento's COVI-TRACE is going to be the gold standard for the literally billions of essential Covid tests that can take place. Only the Sorrento-Columbia COVI-TRACE checks all the boxes here for rapid testing, affordable testing, highly accurate testing, and saliva-based testing. Without any ambiguity, the Sorrento-Columbia COVI-TRACE product is acknowledged as the "BEST IN CLASS" Covid test.
The FDA is desperate for COVI-TRACE to be given an EUA so that the national nightmare of overwhelmed testing labs can be alleviated. We are days away from the start of flu season, the nation is struggling to reopen local economies, schools and colleges are wanting to reopen, and even sports leagues want to play ball. The nation is desperate for the gold standard in Covid testing, COVI-TRACE is that gold standard product.
Nio stock price target raised to $14 from $11 at J.P. Morgan
THIS IS LAST UPGRADE
Because we will not get rid of COVID-19 very soon, this virus represents an extraordinarily large market for Sorrento (and of course for its competitors). We can no longer continue with tests whose results return in 2-3 days or more.The market is so big that we will probably need a lot more quick tests - only with the quick tests from Yale and Sorrento I don't think we can handle it.Sorrento stock is extremely volatile now but this is only due to non-professional traders who do not understand that this stock is not for day trading -the stock has no less than about 9-10 approvals, news or results pending.Why do some sell this stock before the completion of one of these possible catalysts?I read somewhere that fear and greed are the most feared enemies of traders - this is certainly a good reason for these short traders.